Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha) is the enzymatic component of protein kinase A responsible for phosphorylation of serine and threonine residues on target proteins, modulated by cellular levels of cyclic AMP (cAMP). Upon cAMP binding to the regulatory subunit, the catalytic subunit is released, becoming active. It plays essential roles in hormonal signaling pathways, energy metabolism, cell cycle regulation, memory formation, and many other cellular functions. Aberrant PKA C-alpha activity has been implicated in the pathogenesis of various cancers, cardiovascular conditions, and endocrine diseases, making it a validated therapeutic and research target[3][7][8][5].
Small molecules/drugs that elevate cAMP (e.g., beta-adrenergic agonists) indirectly activate PKA by increasing cAMP levels, leading to dissociation of the regulatory subunit and activation of the catalytic subunit[2][3][8].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein kinase cAMP-activated catalytic subunit alpha (PKA C-alpha).